Is Bliss GVS Pharma overvalued or undervalued?

As of 17 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 15.81, an EV to EBITDA of 12.78, and a PEG ratio of 0.89, all of which suggest a favorable valuation relative to growth expectations.
In comparison to its peers, Bliss GVS Pharma stands out with a PE ratio significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both categorized as expensive. Additionally, it has a more attractive EV to EBITDA ratio than many competitors, reinforcing its undervalued status. Notably, Bliss GVS Pharma has outperformed the Sensex over the past year with a return of 38.96% compared to the Sensex's 9.50%, further supporting the argument for its attractive valuation.